Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.

Arnaud Garnier,Karine Brochard,Theresa Kwon, Anne-Laure Sellier-Leclercq,Annie Lahoche,Emma Allain Launay,François Nobili,Mathilde Caillez,Sophie Taque,Jerôme Harambat, Guylhene Michel-Bourdat,Vincent Guigonis,Marc Fila,Sylvie Cloarec,Djeddi Djamal-Dine, Loïc de Parscaux,Lise Allard,Rémi Salomon,Tim Ulinski,Véronique Frémeaux-Bacchi,Christophe Morin,Pascale Olivier-Abbal, Hélène Colineaux, Françoise Auriol,Catherine Arnaud,Isabelle Kieffer,Clara Brusq

Journal of the American Society of Nephrology : JASN（2023）

引用 7|浏览7

暂无评分

摘要

In pediatric STEC-HUS patients, eculizumab treatment does not appear to be associated with improved renal outcome during acute phase of the disease but may reduce long-term kidney sequelae.

查看译文

关键词

hemolytic uremic syndrome, complement, ARF, clinical trial, dialysis, pediatric nephrology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要